Indoco Remedies Board Approves FY 2025-26 Results, Recommends Dividend of Rs. 0.20 Per Share
Indoco Remedies Limited announced the outcome of its Board of Directors meeting held on May 7, 2026. The Board reviewed and approved the Audited Financial Results (Consolidated and Standalone) for the quarter and year ended March 31, 2026.In a key shareholder proposal, the Board recommended a dividend of Rs. 0.20 per equity share, based on the company's face value of Rs. 2/-, for the financial year 2025-2026. This dividend recommendation is subject to the approval of the members at the ensuing Annual General Meeting. The company confirmed that the Statutory Auditors, M/s Gokhale & Sathe, Chartered Accountants, issued an unmodified opinion on the audited financial results.
Quarterly and Annual Performance Overview
The company reported strong revenue growth during the fourth quarter of Fiscal Year 2025-26.For the quarter ended March 31, 2026, Indoco Remedies reported revenues of ₹ 4,291 mn. This marks a significant increase compared to ₹ 3,411 mn recorded during the same quarter of the previous year. The EBITDA to net sales ratio for the quarter stood at 14.7% at ₹ 630 mn, compared to 1.0% at ₹ 35 mn in the corresponding quarter last year.
For the full financial year ending March 31, 2026, the company’s revenues reached ₹ 16,335 mn, significantly higher than the ₹ 14,948 mn recorded in the same period last year. Over the entire fiscal year, the EBITDA to net sales ratio was 9.6% at ₹ 1,572 mn, compared to 8.6% at ₹ 1,280 mn in the prior year.
Ms. Aditi Panandikar, Managing Director of Indoco Remedies Ltd., attributed the robust performance to a good showing in the International Formulations Business, complemented by steady growth in the API & Services Businesses.
Financial Results Snapshot
The financial performance comparison highlights the year-over-year growth across key metrics:| Metric | Q4 Ended Mar 31, 2026 | Q4 Ended Mar 31, 2025 | Full Year Ended Mar 31, 2026 | Full Year Ended Mar 31, 2025 |
|---|---|---|---|---|
| Revenue | ₹ 4,291 mn | ₹ 3,411 mn | ₹ 16,335 mn | ₹ 14,948 mn |
| EBITDA to Net Sales | 14.7% (₹ 630 mn) | 1.0% (₹ 35 mn) | 9.6% (₹ 1,572 mn) | 8.6% (₹ 1,280 mn) |
The company remains a fully integrated, research-oriented pharmaceutical entity with a strong global presence. It operates 10 manufacturing facilities (6 for FDFs and 4 for APIs) and maintains a state-of-the-art R&D Centre and a CRO facility.
INDOCO Stock Price Movement
As of 12:56 PM, Indoco Remedies Limited shares are rallying strongly, climbing ₹9.95 to trade at ₹238.63, marking a 4.35% gain in live trading. The positive momentum is supported by robust buying interest, with the stock trading on a volume of 45,061 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.